Cargando…

Soluble Urokinase‐Type Plasminogen Activator Receptor: A Useful Biomarker for Coronary Artery Disease and Clinical Outcomes?

Detalles Bibliográficos
Autores principales:	Harskamp, Ralf E., Roe, Matthew T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2014
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323826/ https://www.ncbi.nlm.nih.gov/pubmed/25341888 http://dx.doi.org/10.1161/JAHA.114.001431

Ejemplares similares

Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD
por: Böcskei, Renáta M., et al.
Publicado: (2019)

From lactate to soluble urokinase plasminogen activator receptor: The journey for ideal cardiac biomarker: Are we there in 2016?
por: Kapoor, Poonam Malhotra
Publicado: (2016)

Soluble urokinase-type plasminogen activator receptor predicts peripheral artery disease severity and outcomes
por: Höbaus, Clemens, et al.
Publicado: (2021)

Soluble Urokinase Plasminogen Activator Receptor and the Risk of Coronary Artery Disease in Young Chinese Patients
por: Huang, Yuli, et al.
Publicado: (2017)

Prognostic value of soluble urokinase‐type plasminogen activator receptor in coronary artery disease: A meta‐analysis
por: Li, Yang, et al.
Publicado: (2022)

Soluble Urokinase‐Type Plasminogen Activator Receptor and High‐Sensitivity Troponin Levels Predict Outcomes in Nonobstructive Coronary Artery Disease
por: Al‐Badri, Ahmed, et al.
Publicado: (2020)

Urokinase-type plasminogen activator receptor in IgA nephropathy
por: Ahn, Shin-Young, et al.
Publicado: (2014)

Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography
por: Sommerer, Claudia, et al.
Publicado: (2019)

Sex Differences in Circulating Soluble Urokinase‐Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease
por: Mehta, Anurag, et al.
Publicado: (2020)

Clinical value of soluble urokinase type plasminogen activator receptors in chronic kidney disease
por: Ahmed, Reem M., et al.
Publicado: (2019)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma
por: Kouhpayeh, Shirin, et al.
Publicado: (2017)

A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease
por: Spinale, Joann M., et al.
Publicado: (2014)

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor in Obstructive Sleep Apnoea
por: Bocskei, Renata Marietta, et al.
Publicado: (2020)

Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD
por: Gumus, Aziz, et al.
Publicado: (2015)

Soluble Urokinase Plasminogen Activator Receptor as a Diagnostic and Prognostic Biomarker in Cardiac Disease
por: Velissaris, Dimitrios, et al.
Publicado: (2021)

Clinical and prognostic usefulness of soluble urokinase plasminogen activator receptor in hemodialysis patients
por: Wlazeł, Rafał Nikodem, et al.
Publicado: (2018)

Association between serum soluble urokinase-type plasminogen activator receptor and atrial fibrillation
por: Ichihara, Noboru, et al.
Publicado: (2017)

Detection of soluble urokinase type plasminogen activator receptors in children with gingivitis and normal subjects
por: El‑Patal, Mohamed Abd‑Ellatif, et al.
Publicado: (2022)

Soluble urokinase plasminogen activation receptor - An emerging new biomarker of cardiovascular disease and critical illness
por: Cyrille, Nicole B., et al.
Publicado: (2016)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation
por: Rasmussen, Line Jee Hartmann, et al.
Publicado: (2021)

Soluble urokinase plasminogen activator receptor: from biomarker to active participant in atherosclerosis and cardiovascular disease
por: Goodchild, Traci T., et al.
Publicado: (2022)

Soluble Urokinase Plasminogen Activator Receptor as a Marker for Use of Antidepressants
por: Haastrup, Eva, et al.
Publicado: (2014)

Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD
por: Godtfredsen, Nina S., et al.
Publicado: (2018)

Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia
por: van Oort, Pouline M., et al.
Publicado: (2019)

Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis
por: Garnæs, Emilie, et al.
Publicado: (2019)

Soluble urokinase plasminogen activator receptor level in individuals of advanced age
por: Wlazel, Rafal N., et al.
Publicado: (2020)

Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19
por: Luo, Shengyuan, et al.
Publicado: (2022)

Local Production of Soluble Urokinase Plasminogen Activator Receptor and Plasminogen Activator Inhibitor‐1 in the Coronary Circulation Is Associated With Coronary Endothelial Dysfunction in Humans
por: Corban, Michel T., et al.
Publicado: (2018)

Increased circulating soluble urokinase-type plasminogen activator receptor (suPAR) levels in patients with slow coronary flow
por: Emrah, Acar, et al.
Publicado: (2016)

Soluble Urokinase Plasminogen Activator Receptor Level Is an Independent Predictor of the Presence and Severity of Coronary Artery Disease and of Future Adverse Events
por: Eapen, Danny J., et al.
Publicado: (2014)

Soluble Urokinase Plasminogen Activator Receptor Level Is an Independent Predictor of the Presence and Severity of Coronary Artery Disease and of Future Adverse Events
Publicado: (2015)

The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer
por: Blomberg, Kristian, et al.
Publicado: (2021)

Plasma Soluble Urokinase-Type Plasminogen Activator Receptor Is Not Associated with Neurological Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage
por: Kiiski, Heikki, et al.
Publicado: (2017)

Association between Serum Soluble Urokinase-Type Plasminogen Activator Receptor Level and Arterial Stiffness in Chronic Hemodialysis Patients
por: Lin, Wei-Chen, et al.
Publicado: (2023)

Soluble urokinase-type plasminogen activator receptor improves early risk stratification in cardiogenic shock( )
por: Hongisto, Mari, et al.
Publicado: (2022)

Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation
por: Koh, Angela S., et al.
Publicado: (2017)

Plasma Soluble Urokinase Plasminogen Activator Receptor in Children with Urinary Tract Infection
por: Wittenhagen, Per, et al.
Publicado: (2011)

The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia
por: Erkut, Nergiz, et al.
Publicado: (2016)

Soluble urokinase plasminogen activator receptor (suPAR) in the emergency department: An update
por: Velissaris, Dimitrios, et al.
Publicado: (2022)

Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors
Publicado: (1987)

Cannot write session to /tmp/vufind_sessions/sess_vao7o91m9ah8apvn4ccel02hcd